Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2high and D3high receptors

This publication has 24 references indexed in Scilit:

• Radiosynthesis and Evaluation of [¹¹C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography
  Journal of Medicinal Chemistry, 2005
• Dopamine displaces [³H]domperidone from high‐affinity sites of the dopamine D2 receptor, but not [³H]raclopride or [³H]spiperone in isotonic medium: Implications for human positron emission tomography
  Synapse, 2003
• Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand
  European Journal of Pharmacology: Molecular Pharmacology, 1995
• Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors
  European Journal of Pharmacology: Molecular Pharmacology, 1995
• Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor
  European Journal of Pharmacology: Molecular Pharmacology, 1992
• The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
  Movement Disorders, 1989
• Dopamine Receptor Parameters Detected by [³H]Spiperone Depend on Tissue Concentration: Analysis and Examples
  Journal of Neurochemistry, 1984
• Bromocriptine concentration in saliva and plasma after long-term treatment of patients with Parkinson's disease
  European Journal of Clinical Pharmacology, 1980
• Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
  Biochemical Pharmacology, 1973